Legal & General Group Plc Takes Position in CareDx, Inc. $CDNA

Posted by Geri Gentry on Sep 3rd, 2026

Legal & General Group Plc purchased a new stake in CareDx, Inc. (NASDAQ:CDNA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 211,967 shares of the company’s stock, valued at approximately $6,041,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its holdings in CareDx by 1.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock valued at $739,000 after buying an additional 711 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of CareDx by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after acquiring an additional 1,280 shares during the last quarter. Quarry LP acquired a new position in shares of CareDx during the 4th quarter valued at about $25,000. Allspring Global Investments Holdings LLC grew its holdings in shares of CareDx by 11.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 21,242 shares of the company’s stock valued at $380,000 after purchasing an additional 2,151 shares during the period. Finally, SG Americas Securities LLC grew its holdings in shares of CareDx by 8.3% in the first quarter. SG Americas Securities LLC now owns 29,949 shares of the company’s stock valued at $520,000 after purchasing an additional 2,292 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. William Blair raised shares of CareDx to a “hold” rating in a research note on Thursday, July 16th. HC Wainwright reissued a “neutral” rating and issued a $46.00 price target on shares of CareDx in a research note on Friday, July 31st. Weiss Ratings upgraded shares of CareDx from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, August 13th. BTIG Research lifted their price target on shares of CareDx from $45.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Zacks Research upgraded CareDx from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $51.20.

Check Out Our Latest Analysis on CDNA

Insider Transactions at CareDx

In other news, Director Hannah Valantine sold 12,103 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the completion of the transaction, the director directly owned 36,686 shares in the company, valued at $847,813.46. This trade represents a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $29.24, for a total value of $1,166,676.00. Following the completion of the sale, the chief executive officer owned 661,959 shares in the company, valued at $19,355,681.16. This represents a 5.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 110,101 shares of company stock valued at $3,654,308. Corporate insiders own 2.40% of the company’s stock.

CareDx Stock Performance

Shares of CDNA stock opened at $49.60 on Thursday. The firm’s 50 day moving average price is $39.84 and its 200-day moving average price is $27.11. CareDx, Inc. has a one year low of $12.37 and a one year high of $53.67. The firm has a market cap of $2.57 billion, a P/E ratio of 23.96 and a beta of 2.43.

CareDx (NASDAQ:CDNA – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.14. The firm had revenue of $131.95 million during the quarter, compared to the consensus estimate of $114.05 million. CareDx had a net margin of 24.23% and a return on equity of 2.87%. The firm’s revenue for the quarter was up 52.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.16) EPS. As a group, research analysts predict that CareDx, Inc. will post 0.47 EPS for the current fiscal year.

CareDx Company Profile

(Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.